@ Firedup

About the question in the straw - will these tests impact CGS viability or profitability?

I don't think either of these would make CGS redundant.

Cogstate's tests create a baseline to test performance against, or more specifically degradation of performance against (as the disease worsens)

A blood test or optical test would, I imagine just test for susceptibility or that you have it or don't have it, not the grade to which you have it and are impacted by it.

Note. I’m not a medical person.